AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibitsprogression of human ovarian cancer

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 804-811

  Brunckhorst, Melissa K ^a   Lerner, Dimitry ^a,b   Wang, Shaomeng ^c   Yu, Qin ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Carboplatin; Chemosensitization; Ovarian cancer; Smac mimetic; Therapeutic agent

Indexed keywords

ANTINEOPLASTIC AGENT; AT 406; CARBOPLATIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PROTEIN DEGRADATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZOCINES; BENZHYDRYL COMPOUNDS; CARBOPLATIN; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INHIBITORY CONCENTRATION 50; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863448875     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20563     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
2. Bell R, Petticrew M, Luengo S, Sheldon TA. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998; 2:1-84; PMID:9561894.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329:1550-9; PMID:8155119; http://dx.doi. org/10.1056/NEJM199311183292108.
4. Ma JJ, Chen BL, Xin XY. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol 2009; 146:222-6; PMID:19758744; http://dx.doi. org/10.1016/j.ejogrb.2009.06.011.
5. Tirrò E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, et al. Altered expression of c-IAP1, survivin and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66:4263-72; PMID:16618750; http://dx.doi.org/10.1158/0008-5472.CAN-05-3248.
6. Zhang S, Ding F, Luo A, Chen A, Yu Z, Ren S, et al. XIAP is highly expressed in esophageal cancer and its downregulation by RNAi sensitizes esophageal carcinoma cell lines to chemotherapeutics. Cancer Biol Ther 2007; 6:973-80; PMID:17611394.
7. Li Y, Jian Z, Xia K, Li X, Lv X, Pei H, et al. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006; 32:288- 96; PMID:16628085; http://dx.doi.org/10.1097/01. mpa.0000218314.67111.fb.
8. + cells. Br J Haematol 2002; 118:521-34; PMID:12139741; http://dx.doi.org/10.1046/j.1365-2141. 2002.03637.x.
9. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004; 14:567-78; PMID:15666998.
10. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Downregulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000; 60:5659-66; PMID:11059757.
11. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005; 96:287-95; PMID:15661210; http://dx.doi.org/10.1016/j.ygyno.2004.10.026.
12. Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, et al. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol Oncol 2005; 97:413- 21; PMID:15863139; http://dx.doi.org/10.1016/j. ygyno.2004.12.055.
13. He XP, Ota T, Liu P, Su CQ, Chien J, Shridhar V. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells. Cancer Res 2010; 70:3109-18; PMID:20388781; http://dx.doi.org/10.1158/ 0008-5472.CAN-09-3557.
14. Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 2008; 122:1430-4; PMID:18027851; http://dx.doi.org/10.1002/ijc.23278.
15. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102:33-42; PMID:10929711; http://dx.doi. org/10.1016/S0092-8674(00)00008-8.
16. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102:43-53; PMID:10929712; http://dx.doi.org/10.1016/S0092- 8674(00)00009-X.
17. Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C, et al. Proapoptotic protein Smac mediates apoptosis in cisplatin- resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 2012; 287:68-80; PMID:22052903; http://dx.doi.org/10.1074/jbc. M111.271205.
18. Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 2007; 105:481-92; PMID:17292950; http://dx.doi.org/10.1016/j. ygyno.2007.01.011.
19. Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem 2011; 54:2714- 26; PMID:21443232; http://dx.doi.org/10.1021/ jm101505d.
20. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNFα-dependent manner. Cell Death Differ 2010; 17:1645-54; PMID:20431601; http://dx.doi.org/10. 1038/cdd.2010.44.
21. Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005; 12:509-14; PMID:15706355.
22. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68:9384-93; PMID:19010913; http://dx.doi.org/10.1158/0008-5472.CAN-08- 2655.
23. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncol Res 2003; 13:399-404; PMID:12725530.
24. Bai Y, Liu YJ, Wang H, Xu Y, Stamenkovic I, Yu Q. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 2007; 26:836-50; PMID:16953231; http://dx.doi.org/10.1038/sj.onc.1209849.
25. Brunckhorst MK, Wang H, Lu R, Yu Q. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res 2010; 70:7283-93; PMID:20823154; http://dx.doi. org/10.1158/0008-5472.CAN-09-4125.
26. Lau YK, Murray LB, Houshmandi SS, Xu Y, Gutmann DH, Yu Q. Merlin is a potent inhibitor of glioma growth. Cancer Res 2008; 68:5733-42; PMID:18632626; http://dx.doi.org/10.1158/0008-5472.CAN-08-0190.
27. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010; 70:2455-64; PMID:20197461; http://dx.doi. org/10.1158/0008-5472.CAN-09- 2505.